Безопасността на бексаротен беше изследвана при клинични проучвания на 193 пациенти с кожен
The safety of bexarotene has been examined in clinical studies of 193 patients with CTCL who received bexarotene for up to 118 weeks and in 420 non-CTCL cancer patients in other studies.